Trisectionectomies significantly improve survival for patients with localized Bismuth-Corlette type II-III perihilar cholangiocarcinoma.

• Overall survival improved to 52.4 months with trisectionectomy vs. 31 months for extended hemihepatectomy (p < 0.001).
• R0 resection rates were higher with trisectionectomies (83.9% vs. 75.8%, p = 0.037).

Consider trisectionectomies for appropriate patients to enhance oncological outcomes without increasing significant morbidity or mortality risks.

• Grade B-C liver failure occurred more frequently with trisectionectomies (23.4% vs. 11.3%, p = 0.002).

Surgeons can now identify non-functioning pancreatic neuroendocrine tumors at high risk for early recurrence preoperatively.

• Early recurrence occurred in 11% of patients, with a median disease-free survival of 16 months.
• Neoplastic venous thrombosis predicted a 71% chance of early recurrence; without it, patients with a KI-67 index ≥5% and tumor size ≥3 cm had a 19-41% recurrence risk.

Incorporating this model can enhance surgical decision-making and patient counseling regarding prognosis.

Surgeons now have a validated model to identify patients at high risk for early non-curative recurrence after liver resection for hepatocellular carcinoma (HCC), crucial for tailoring postoperative care.

• Early non-curative recurrence significantly increases overall survival risk (hazard ratio 5.39).
• Median survival drops from 178.6 months to just 34.7 months in early recurrence cases (p < 0.001).

Implementing this model can refine patient monitoring and improve long-term outcomes after HCC surgery.

• Key predictive factors include elevated alpha-fetoprotein, larger tumor size, multiple tumors, portal invasion, and serosal invasion.

Using indocyanine green (ICG) fluorescence navigation in laparoscopic hepatectomy leads to better outcomes for hepatic hemangioma patients.

• Median blood loss: 100 ml (ICG) vs 200 ml (conventional), p < 0.001.
• Hospital stays shortened: 5.9 days (ICG) vs 7.1 days (conventional), p < 0.001.

For patients with an Iwate score above 9, ICG significantly reduced operative time (158 min vs 224 min, p < 0.001) and hepatic inflow occlusions.

Consider ICG navigation to enhance surgical precision and patient recovery.

Surgical resection significantly improves survival for hepatocellular carcinoma patients who reach complete response following triple therapy.

• One-, two-, and three-year survival rates post-surgery were 96.0%, 90.8%, and 90.8%, compared to 91.3%, 85.8%, and 73.1% for nonsurgical management.
• Patients who underwent surgery saw 70.9% achieve pathological complete response; however, the overall complication rate was 24.2%.

Surgical resection should be strongly considered for these patients to enhance outcomes.